Spyre Therapeutics (SYRE)
NASDAQ:SYRE
SYRE Stock Chart & Stats
$47.58
-$0.27(-1.11%)
At close: 4:00 PM EST
$47.58
-$0.27(-1.11%)
Day’s Range― - ―
52-Week Range$10.91 - $51.06
Previous CloseN/A
Volume84.75K
Average Volume (3M)845.00K
Market Cap
$3.74B
Enterprise Value$2.79B
Total Cash (Recent Filing)$756.53M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.67
Next Earnings
May 07, 2026EPS Estimate
-0.67Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.70
Shares Outstanding78,540,160
10 Day Avg. Volume882,972
30 Day Avg. Volume844,997
Financial Highlights & Ratios
PEG Ratio1.94
Price to Book (P/B)15.85
Price to Sales (P/S)0.00
P/FCF Ratio-66.98
Enterprise Value/Market Cap0.75
Enterprise Value/Revenue30.81
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-15.56
Forecast
1Y Price Target
$65.22Price Target Upside37.07% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)-2.92
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Combination Therapy DevelopmentA co-funding agreement supporting an IL-23 plus TNFα co-antibody validates the combination strategy and could accelerate advancement of the company's combination regimens into later-stage trials.
Long-acting TL1A DifferentiationNext-generation TL1A antibodies engineered for extended half-life and improved receptor coverage could enhance efficacy and enable less frequent dosing, creating a potential clinical and commercial differentiator versus first-generation agents.
Rheumatology Expansion And EnrollmentStrong enrollment in the rheumatoid arthritis substudy, together with human genetic and preclinical evidence linking TL1A to joint disease, increases the likelihood that positive rheumatology readouts could broaden indications and market opportunity.
Bears Say
Competitive Pressure From New TherapiesEmergence of oral IL-23 candidates and newer small molecule agents raises competitive pressure in inflammatory bowel disease and could limit market share and pricing power if those therapies prove effective.
Financial Runway And Funding RiskCurrent cash burn and a limited financial runway increase the risk that additional capital will be required to fund development, which could lead to dilution or delays in key programs.
Outcome-dependent Competitor OverhangPending results from competitor combination trials create an outcome-dependent overhang that could materially affect sentiment if rival data outperform expectations.
Spyre Therapeutics News
SYRE FAQ
What was Spyre Therapeutics’s price range in the past 12 months?
Spyre Therapeutics lowest stock price was $10.91 and its highest was $51.06 in the past 12 months.
What is Spyre Therapeutics’s market cap?
Spyre Therapeutics’s market cap is $3.74B.
When is Spyre Therapeutics’s upcoming earnings report date?
Spyre Therapeutics’s upcoming earnings report date is May 07, 2026 which is in 32 days.
How were Spyre Therapeutics’s earnings last quarter?
Spyre Therapeutics released its earnings results on Feb 19, 2026. The company reported -$0.7 earnings per share for the quarter, beating the consensus estimate of -$0.709 by $0.009.
Is Spyre Therapeutics overvalued?
According to Wall Street analysts Spyre Therapeutics’s price is currently Undervalued.
Does Spyre Therapeutics pay dividends?
Spyre Therapeutics does not currently pay dividends.
What is Spyre Therapeutics’s EPS estimate?
Spyre Therapeutics’s EPS estimate is -0.67.
How many shares outstanding does Spyre Therapeutics have?
Spyre Therapeutics has 78,540,160 shares outstanding.
What happened to Spyre Therapeutics’s price movement after its last earnings report?
Spyre Therapeutics reported an EPS of -$0.7 in its last earnings report, beating expectations of -$0.709. Following the earnings report the stock price went up 14.282%.
Which hedge fund is a major shareholder of Spyre Therapeutics?
Currently, no hedge funds are holding shares in SYRE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Spyre Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$65.22 (37.07% Upside)
$65.22 (37.07% Upside)
Blogger Sentiment
Bullish
SYRE Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 4.5M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.6%
Last 30 Days ▲ 24.7%
Last 30 Days ▲ 24.7%
News Sentiment
Bullish
Bullish news 67%
Bearish news 33%
Bearish news 33%
Technicals
SMA
Positive
20 days / 200 days
Momentum
207.16%
12-Months-Change
Fundamentals
Return on Equity
-29.44%
Trailing 12-Months
Asset Growth
27.82%
Trailing 12-Months
Company Description
Spyre Therapeutics
Spyre Therapeutics, Inc., a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease). The company is also developing SPY002, a human monoclonal antibody (mAb)candidates designed to bind to tumor necrosis factor-like ligand 1A; and SPY120, a combination of SPY001 (anti-a4ß7) and SPY002 (anti-TL1A) antibodies, which are in preclinical studies. In addition, its other early-stage programs include SPY003, an anti-IL-23 mAb; SPY004, a novel mechanism of action (MOA) mAb; SPY130, a combination of anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination of anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. Spyre Therapeutics, Inc. was incorporated in 2013 and is based in Waltham, Massachusetts.
SYRE Stock 12 Month Forecast
Average Price Target
$65.22
▲(37.07% Upside)
Technical Analysis
EyePoint Pharmaceuticals
―
Praxis Precision Medicines
―
ARS Pharmaceuticals
―
Oculis Holding
―
Upstream Bio, Inc.
―
Ownership Overview
7.34% Insiders
25.00% Mutual Funds
54.15% Other Institutional Investors
2.29% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---